Galmed Pharmaceuticals Ltd. (GLMD) News

Galmed Pharmaceuticals Ltd. (GLMD): $0.35

0.02 (+4.88%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add GLMD to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#345 of 503

in industry

Filter GLMD News Items

GLMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest GLMD News From Around the Web

Below are the latest news stories about GALMED PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate GLMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

William White on InvestorPlace | November 21, 2023

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

Yahoo | November 20, 2023

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramch

Yahoo | September 26, 2023

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to main

Yahoo | September 22, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!

William White on InvestorPlace | August 18, 2023

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering").

Yahoo | July 14, 2023

Why Is Carvana (CVNA) Stock Down 5% Today?

Carvana (CVNA) stock is falling on Thursday after JPMorgan analyst Rajat Gupta downgraded the used-car retailer's shares.

William White on InvestorPlace | July 13, 2023

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?

Galmed Pharmaceuticals (GLMD) stock is on the move Thursday after the medical company priced a public offering of its shares.

William White on InvestorPlace | July 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.

William White on InvestorPlace | July 13, 2023

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, is delighted to announce the first step in its strategic partnership with OnKai, where OnKai will apply its artificial intelligence (AI), models for enrollment and execution of clinical trials in underserved communities, starting with Galmed's innovative Primary Sclerosing Cholangitis (PSC) clinical development program.

Yahoo | July 10, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!